Efficacy and safety of cyclical etidronate therapy in the long-term treatment of osteoporosis

Reviews in Contemporary Pharmacotherapy

Volumn 9, Issue 4, 1998, Pages 255-260

  Miller, Paul D ^a  

^a Colorado Center for Bone Research ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; ESTROGEN; ETIDRONIC ACID;

ADULT; BONE BIOPSY; BONE MASS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; FEMALE; HEALTH CARE COST; HUMAN; LONG TERM CARE; META ANALYSIS; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; VERTEBRA FRACTURE;

EID: 0031835061     PISSN: 09548602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Axelrod DW, Teitelbaum SL. Results of long-term cyclical etidronate therapy: histomorphometry and clinical correlates. J Bone Miner Res 1994; 9 (Suppl 1): S136.
2. Christiansen C, Christiansen MS, Transbø L. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet 1981; i: 459-161.
3. Colditz GA, Hankinson S, Hunger D et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332: 1589-1593.
4. Dempster DW. Exploiting and bypassing the bone remodeling cycle to optimize the treatment of osteoporosis. J Bone Miner Res 1997; 12: 1152-1154.
5. Diamond T, McGuigan L, Barbagallo S, Bryant C. Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women. Am J Med 1995; 98: 459-163.
6. Faulkner KG, McClung MR. Quality control of DXA instruments in multicenter trials. Osteoporosis Int 1995; 5: 218-227.
7. Fleisch HA. Bisphosphonate: preclinical aspects and use in osteoporosis. Ann Intern Med 1997; 29: 55-62.
8. Fleisch H, Russell RGG, Francis MD. Bisphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture in vivo. Science 1969; 165: 1264-1266.
9. Fujita T, Orimo H, Inoue T et al. Double-blind comparative study with alfacalcidol of etidronate disodium (EHDP) in involutional osteoporosis. Clin Eval 1993; 21: 261-302.
10. Gertz BJ, Holland SH, Kline WE Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 1995; 58: 288-298.
11. Gluer C-C, Faulkner KG, Estilo MJ, Engelke K, Rosin J, Genant H. Quality assurance for bone densitometry research studies: Concept and impact. Osteoporosis Int 1993; 3: 227-235.
12. Grodstein F, Stampfer M, Colditz G et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336: 1769-1775.
13. Hanhijarvi H, Elamaa I, Karlsson M, Lauren L. Pharmacokinetics of disodium clodronate after daily intravenous infusions during five consecutive days. Int J Clin Pharmacol Ther Toxicol 1989; 27: 602-606.
14. Harris ST, Watts NB, Jackson RD et al. Four-year study of intermittent cyclical etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 1993; 95: 557-567.
15. Heaney RP. The remodeling transient: implications for the interpretation of clinical studies of bone mass change. J Bone Miner Res 1994; 9: 1515-1523.
16. Heaney RP, Saville PD. Etidronate in postmenopausal osteoporosis. Clin Pharmacol Ther 1976; 20: 593-604.
17. Heaney RP, Yates AJ, Santora AC. Bisphosphonate effects and the bone remodeling transient. J Bone Miner Res 1997; 12: 1143-1151.
18. Hodsman AB. Effects of cyclical therapy for osteoporosis using an oral regimen of inorganic phosphate and sodium etidronate: a clinical and bone histomorphometric study. Bone Miner 1989; 5: 201-212.
19. Hughes DE, Luckman SR, Russell RGG, Rogers M. Involvement of the mevalonate pathway in osteoclast apoptosis and the mechanism of action of bisphosphonates. Bone 1997; 20 (Suppl 1): 110S.
20. Khan SA, Kanis JA, Vasikaran S et al. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res 1997; 12: 1700-1707.
21. Landman JO, Hamdy NAT, Pauwels EKJ, Papapoulos SE. Skeletal metabolism in patients with osteoporosis after discontinuation of long term treatment with oral pamidronate. J Clin Endocrinol Metab 1995; 80: 3465-3468.
22. Liberman U, Weiss S, Broil J et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333: 1437-1443.
23. Miller PD, Erickson AL. Long-term intermittent cyclical etidronate therapy (ICT) for postmenopausal osteoporosis (PMO). Calcif Tissue Int 1995; 56: 493.
24. Sato M, Grasser W, Endo N et al. Bisphosphonate action: alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991; 88; 2095-2105.
25. Shinoda AH, Aamek G, Felix R, Fleisch H, Sohenk R, Hagan P. Structure-activity relationships of various bisphosphonates. Calcif Tissue Int 1993; 35: 87-99.